


CONTROVERSIES IN NEUROLOGY












Welcome to Kyiv,

Welcome to the 1st Ukrainian Congress on Controversies in Neurology!

We are proudly hosting this year the 1st Ukrainian Regional Congress on Controversies in Neurology – a unique science and education event where physicians can meet world leading experts of major neurological fields and find out the new information on the most nowadays issues. The unique format of the congress in the form of discussion and debates provides a platform for international experts to exchange and compare experience

We sincerely hope you'll enjoy the Congress and beautiful city Kyiv!

Learn more: www.rimon.in.ua/cony/2017 www.ulae.org.ua





THE 1ST REGIONAL UKRAINIAN CONGRESS CONTROVERSIES IN NEUROLOGY



WELCOME address

Dear Friends and Colleagues!

From the moment of its establishment in 2007, the World Congress has become a unique science and education event where physicians can meet world leading experts of major neurological fields and find out the new information on the most nowadays issues. The unique format of the congress in the form of discussion and debates provides a platform for international experts to exchange and compare experience and it attracts attention of more and more specialists. The purpose of the Congress is to produce the most relevant clinical data and the latest scientific information, helping in every day patient care.

The main topics that will be discussed at the First Regional Ukrainian Congress on Controversies in Neurology are Epilepsy, Headache & pain, Neuropsychiatry & Behavioral Neurology, Parkinson's disease & other movement disorders, Multiple sclerosis. The moderators of the work sections of the congress will act together with leading Ukrainian specialists and international experts, who participated in world congresses of the same format.

The multidisciplinary approach will offer the latest world-wide information, presented in a unique format, for different specialists, such as neurologists, psychiatrists, family doctors and others.

We cordially invite all those who are interested to join this unique event. We are glad to welcome guests from all over Ukraine and foreign guests in the capital of Ukraine, Kyiv. We hope that an interesting scientific and practical program of Congress, along with communication with colleagues and acquaintance with a beautiful city, will remain in your memory for a long time.

We are waiting for a meeting with you at the 1st Ukrainian Regional Congress on Controversies in Neurology in Kyiv!

With best regards,

International Organising committee

Prof. Amos D. Korczyn



Local Organising committee

Prof. Volodymyr Smolanka



Prof. Andriy Dubenko



COMMITTEE

International Organising committee World Congress on Controversies in Neurology,

Prof. Amos D. Korczyn

Local Organising committee

SI "Institute of neurology, psychology and

Narcology NAMS Ukraine",

Prof. Andriy Dubenko

Uzhhorod National University, Prof. Volodymyr Smolanka

Ukrainian Association of

Neuropsychopharmacology,

Prof. Volodymyr Korostiy

Ukrainian League Against Epilepsy,

Prof. Andriy Dubenko

Charitable Foundation Research Innovations in Medicine "RIMON", Nataliya Pryanykova

Technical organizer

Projects Inn, LLC http://projects-inn.com



GENERAL INFORMATION

WELCOME!

Dear Friends and Colleagues,

We are proud to announce that the 1st Ukrainian Regional Congress on Controversies in Neurology will take place in Kyiv, Ukraine in November, 23-24 2017.

Controversies in Neurology a unique educational congress where physicians can meet with outstanding experts in major neurological fields and can be updated on the most pressing clinical questions of the day. We provide a platform for international experts to discuss and compare experiences, enable participants to discuss and debate unresolved issues with world leaders in the field. The Congress aims at providing the most available relevant data armoring the clinician with reliable, up-to-date scientific information, helping in everyday patients care.

In recent years our congresses involve more participants from different fields and various regions. We are interested to develop the regional representation. With active endorsement and support from Ukrainian colleagues, we delighted to launch The 1st Ukrainian Regional Congress on Controversies in Neurology in Kyiv.

For the 1st regional Ukrainian congress we selected the most current topics: Epilepsy, Headache & pain, Neuropsychiatry & Behavioral Neurology, Parkinson's disease & other movement disorders, Multiple sclerosis

There are a number of partnership opportunities available, including industry-sponsored activities. In addition, we would be happy to tailor a sponsorship package to your specific needs.

We cordially invite you to join us in the beautiful city Kyiv!

About Kyiv

There are cities that symbolize a nation and Kyiv is one of them. Kyiv is the soul of Ukraine, playing a key part in the past, present and future of this country. One of the most beautiful cities in the world, Kyiv is covered in a sea of greenery, which can be seen everywhere - in its many parks, boulevards and gardens. At every corner of every street you will find beautiful historic sites.

Today we are witnessing a great time in Kyiv's and in Ukraine's history. With the population of over three million, the same as Rome, Paris, and Madrid, changes are taking place at an amazing pace. At the same time, Kyiv faces challenges that other modern European cities face as well

For more information on Kyiv, please visit Kyiv city guide http://www.inyourpocket.com/kyiv

LOCATION

Kyiv, Ukraine

DATES

November, 23-24 2017

CONGRESS VENUE

PREMIER HOTEL RUS KYIV, 4 Hospitalna St., Ukraine, https://hotelrus.phnr.com/en

TRANSPORTATION

Distance from the venue to: Boryspil International Airport – 40 km, Zhuliany International Airport – 14 km, Central Railway Station – 5 km, River Station – 5 km.

How to get here:

Subway: nearest station – «Palats Sportu», green line

REGISTRATION AND HOSPITALITY DESK

Wednesday, November 22: 14.00-18.00 (Elite Hall, 2nd floor) Thursday, November 23: 08.00-19.00 (Foyer 1st floor) Friday, November, 24: 07.30-16.30 (Foyer 1st floor)

LANGUAGE

The official languages of the congress are English / Ukrainian. During the entire work of the Congress, two-way simultaneous interpretation is provided. You can also make a report in Russian.

SPEAKERS ROOM OPENING HOURS AT THE PREMIER HOTEL RUS (HALL ELITE)

Thursday, November 23: 08.00-19.00 Friday, November, 24: 08.00-14.00

EXHIBITION OPENING HOURS AT THE PREMIER HOTEL RUS (HALL ELITE)

Thursday, November 23: 08.00-19.00 Friday, November, 24: 08.00-16.00

LUNCHES & COFFEE BREAKS

Lunch and Coffee will be served for registered participants according to the times listed in the timetable

CME ACCREDITATION

The 1st Regional Ukrainian Congress on Controversies in Neurology Kyiv, Ukraine, 23/11/2017-24/11/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 13 European CME credits (ECMEC®s) Each medical specialist should claim only those credits that he/she actually spent in the educational activity

CERTIFICATE OF ATTENDENCE

All registered participants will receive Certificate of attendance in congress kit

INTERNET

There will be free Wifi in the public area of the PREMIER HOTEL RUS, and a complimentary charging stations for electronics

SMOKING POLICY

In accordance with the policy of the congress, this is a non-smoking congress

SAFETY AND SECURITY

Please do not leave any bags or other personal belongings unattended at any time, whether outside or inside the session/exhibition halls

PASSPORT AND VISA

Visitors from EU, USA, Canada, Britain can enter the Ukraine without a visa. A valid passport is all you need to enter Ukraine. Other nationals are advised to contact the embassy to check visa requirements for Ukraine

Information about visa requirements can be found on the World Travel Guide website: https://www.worldtravelguide.net/guides/europe/ukraine/

CURRENCY

The local currency is the UAH (€)

ACCOMODATION

PREMIER HOTEL RUS KYIV, 4 Hospitalna St., Ukraine https://hotelrus.phnr.com/en

CME ACCREDITATION: 13 CREDIT POINTS!

THE 1ST Regional Ukrainian Congress on Controversies in Neurology is accredited by the European Accreaditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialist. The EACCME is an institution of the European Union of Medical Specialists (UEMS)



www.uems.net

PROFESSIONAL CONGRESS ORGANIZER

Charitable foundation Research Innovations in Medicine "RIMON" Velyka Zhytomirska st., 20, 9 fl., Business centre "Panorama", Kyiv, Ukraine Tel/Fax: +38 044 537 5277, E-mail: foundation@rimon.in.ua

Please do not hesitate to contact the Secretariat if you require any additional information or assistance. Please address all correspondence to foundation@rimon.in.ua

For more information please visit www.rimon.in.ua

INTERNATIONAL EXPERTS

Amos D. Korczyn (Tel Aviv, Israel)



Professor, Chairman of the Scientific Medical Board of the Israeli Alzheimer's disease association (EMDA), member of the SAB of Alzheimer Disease International (ADI), an honorary member of the neurological societies of Israel, Serbia. Poland and Russia.

Section:

PLENARY SESSION,

NEUROPHSYCHIATRY AND BEHAVIORAL NEUROLOGY

Aydin Gozalov (Copenhagen, Denmark)



Professor, Consultant Neurologist-Headache Specialist, MD, PhD
Danish Headache Center,
Department of Neurology Glostrup Hospital.

Section:

HEADACHE & PAIN

University of Copenhagen

Dimos-Dimitrios D. Mitsikostas (Athens, Greece)



Associate Professor of Neurology, Aeginition Hospital, heading the Headache Unit, the MS Unit, The Clinical Trials Unit and the stroke Unit of the 1se Neurology Department. President of the Hellenic Headache Society (2015–2018)

Section:

HEADACHE & PAIN





Doctor, Director, Georgian Institute of Health, President, Georgian Headache Society, Ex-Director World Health Organization program «Drug Policy» (1999–2000), Neurologist at the Ministry of Internal Affairs, senior specialist (2001–2003)

Section:

HEADACHE & PAIN

Horst Przuntek
(Bochum, Germany)

Professor, Dr., Department of Neurologe, Ruhr University of Bochum



Section:

PARKINSON'S DISEASE & MOVEMENT DISORDERS,
MULTIPLE SCLEROSIS

llan Blatt (Ramat Gan, Israel)



Professor, Past President of the International League Against Epilepsy, Epilepsy Clinic, Dept. Of of Neurology at the Chaim Sheba Medical Center.

Section:

EPILEPSY

10 ← 11



Jaime Kulisevsky (Barcelona, Spain)



MD, PhD, Scientific Director of Institut de Recerca (Barcelona)

Dr. Kulisevsky is Associate Professor of Neurology at the University of Barcelona (UB), Professor of Research at the Open University of Catalonia (UOC) and Director of the Movement Disorders Unit at the HSCSP.

Section:

PARKINSON'S DISEASE & MOVEMENT DISORDERS

Konrad Rejdak (Warsaw, Poland)



Professor, Department of Neurology, Medical University of Lublin & Medical Research Center in Warsaw, Poland

Section:

EPILEPSY

Lars Bendtsen (Copenhagen, Denmark)



MD, PhD, Dr.Med.Sci

Associate Professor at the Department of Neurology and Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen.

Section:

HEADACHE & PAIN

Messoud Ashina (Copenhagen, Denmark)



Professor of Neurology & Chief Consultant,
Director of the Human Migraine Research Unit
Department of Neurology & Danish Headache Center,
Rigshospitalet Glostrup
Faculty of Health and Medical Sciences,
University of Copenhagen

Section:

HEADACHE & PAIN

Morris Freedman (Toronto, Canada)



Dr., Head of Neurology and Medical Director of Cognition and Behaivors at Baycrest Centre for Geriatric Care

Section:

NEUROPHSYCHIATRY AND BEHAVIORAL NEUROLOGY



CONGRESS TIMETABLE

Wednesday	, November 22, 2017	HALL ELITE 2nd FLOOR		
		14:00-18:00	F	Registration
		19:00	Welcome reception	(Restaurant RUS 2ND FLOOR)
Thursday, N	ovember 23, 2017			
	Hall A	Hall B+C+D	Hall F	Hall E
09:00-11:00	OPENING SESSION	I AND PLENARY LECTURES	Chairs: Amos D. Korczyn, Is	srael & Volodymyr Smolanka, Ukraine
11:00-12:00		Coffee Break	(HALL ELITE 2nd FLOOR)	
12:00-14:00	MULTIPLE SCLEROSIS: CHANGES IN TREATMENT PARADIGM Industry supported symposium Supported by Roche	NEUROPSYCHIATRY AND BEHAVIORAL NEUROLOGY Section heads: Morris Freedman, Canada; Volodymyr Korostiy, Ukraine		EPILEPSY Section heads: Konrad Rejdak, Poland; Tetyana Litovchenko, Ukraine
14:00-15:00		Lunch Break	(HALL ELITE 2nd FLOOR)	
15:00-17:00	PARKINSON'S DISEASE & MOVEMENT DISORDERS Section heads: Jaime Kulisevsky, Spain; Tetyana Slobodin, Ukraine	NEUROPSYCHIATRY AND BEHAVIORAL NEUROLOGY Section heads: Morris Freedman, Canada; Volodymyr Korostiy, Ukraine	MULTIPLE SCLEROSIS Section head: Tetyana Muratova, Ukraine	EPILEPSY Section heads: Konrad Rejdak, Poland; Tetyana Litovchenko, Ukraine
17:00-17:15		Coffee Break	(HALL ELITE 2nd FLOOR)	
17:15-19:15	PARKINSON'S DISEASE & MOVEMENT DISORDERS Section heads: Jaime Kulisevsky, Spain; Tetyana Slobodin, Ukraine	NEUROPSYCHIATRY AND BEHAVIORAL NEUROLOGY Section heads: Morris Freedman, Canada; Volodymyr Korostiy, Ukraine	MULTIPLE SCLEROSIS Section head: Tetyana Muratova, Ukraine	



Friday, November 24, 2017

Mikhaylo Oros, Ukraine

CLOSING CEREMONY

HALL VENICE 2nd FLOOR

08:00-09:00

Meet the expert Breakfast session
Supported by Sanofi Genzyme

TREATABLE NEUROMUSCULAR DISEASES. POMPE DISEASE.


Prof. Andoni Urtizberea, France

	Hall A	Hall B+C+D	Hall F	Hall E
09:00-11:00	HEADACHE & PAIN Section heads: Messoud Ashina, Denmark; Mikhaylo Oros, Ukraine	EPILEPSY Section heads: Konrad Rejdak, Poland; Tetyana Litovchenko, Ukraine	MULTIPLE SCLEROSIS Section head: Tetyana Muratova, Ukraine	
11:00-11:30		Coffee Break	(HALL ELITE 2nd FLOOR)	
11:30-13:30	HEADACHE & PAIN Section heads: Messoud Ashina, Denmark; Mikhaylo Oros, Ukraine	PARKINSON'S DISEASE & MOVEMENT DISORDERS Section heads: Jaime Kulisevsky, Spain; Tetyana Slobodin, Ukraine	MULTIPLE SCLEROSIS Section head: Tetyana Muratova, Ukraine	YOUNG INVESTIGATOR SCHOLARSHIP Section head: Natalia Kufterina, Ukraine
13:30-14:30		Lunch Break	(HALL ELITE 2nd FLOOR)	
14:30-16:30	HEADACHE & PAIN Section heads: Messoud Ashina, Denmark;			

16

16:30

FLOORPLAN PREMIER HOTEL RUS KYIV





THE 1st REGIONAL UKRAINIAN CONGRESS November 23–24, 2017 Kyiv, Ukraine

PROGRAM BY SECTIONS



При будь-яких активних ознаках захворювання

РОЗПОЧНІТЬ ЛІКУВАННЯ ПРЕПАРАТОМ

У двох ідентичних 2-річних дослідженнях порівняно із застосуванням високих доз ІФН β-1а* у пацієнтів із РРС





рівняно із застосуванням









ПЕРЕВАЖАЮЧІ КЛІНІЧНІ РЕЗУЛЬТАТИ зі зниженням щорічної частоти інвалідності порівняно із застосуванням високих доз **І**ФН β-1а^{2, 3}

Тродемонстрован СПРИЯТЛИВИЙ ПРОФІЛЬ БЕЗПЕКИ1-3 ЗАСТОСУВАННЯ КОЖНІ 6 МІСЯЦІВ", функцій серцево-судинної системи або рівня лімфоцитів¹

ОКРЕВУС® призначається для лікування дорослих пацієнтів із рецидивуючою (РРС) або первинно прогресуючою (ППРС) формами розсіяного склерозу.

Коротка інформація щодо медичного застосування препарату ОКРЕВУС®



THE 1st REGIONAL UKRAINIAN CONGRESS

November 23-24, 2017 Kyiv, Ukraine

Wednesday, November 22, 2017 PRECONGRESS DAY

HALL ELITE 2nd FLOOR

14:00-18:00 Registration

> 19:00 Welcome reception (Restaurant RUS 2nd FLOOR)

Thursday, November 23, 2017 **PLENARY SESSION**

Hall A

OPENING SESSION AND PLENARY LECTURES 09:00-11:00

CHAIRS:

Amos D. Korczyn, Israel, Volodymyr Smolanka, Ukraine,

Andriy Dubenko, Ukraine

Welcome remarks and invitation to the 1st Regional Ukrainian 09:00-09:30

Congress on Controversies in Neurology in Kyiv

Andriy Dubenko, Ukraine, Amos D. Korczyn, Israel

Plenary lecture 09:30-10:00

Are «functional» neurological diseases really psychogenic?»

Amos D. Korczyn, Israel

10:00-10:30 Plenary lecture

«Minor Strokes» – Big Problems

Tamara Mishchenko, Ukraine

10:30-11:00 Plenary lecture

Paraneoplastic syndromes in neurology practice

Eugen Dubenko, Ukraine; Dmytro Kovalenko, Ukraine

HALL ELITE 2nd FLOOR

Coffee Break 11:00-12:00



4th East European Course of Epilepsy

AGE ASPECTS OF EPILEPSY









Call for ILAE-CEA/ULAE BURSARY application – final application till 20 April 2018
Registration opened – final registration till 11 May 2018

http://ulae.org.ua

EPILEPSY

November 23-24, 2017 Kyiv, Ukraine

Thursday, November 23, 2017

Hall E	
	CHAIRS: Lidiya Maryenko, Ukraine; Volodymyr Kharytonov, Ukraine
12:00-13:00	Debate: Are generics equally effective and safe as original AEDs
	Capsule: Generics used extensively in different countries. For patients with epilepsy, the rules for using generic drugs have their own requirements.
12:00-12:10	Debate host: <i>Ilan Blatt,</i> Israel
12:10-12:25	YES: Taras Studenyak, Ukraine
12:25-12:40	NO: Ludmila Tantsura, Ukraine
12:40-13:00	Discussion and rebuttals
13:00-14:00	Debate: Whether VNS therapy is alternative to other methods of surgical treatment in pharmacoresistant epilepsy?
	Capsule: About 30% of patients epilepsy is remained resistant to therapy. Application of VNS and other surgical methods in a number of cases allows to overcome resistance. Whether can replace application of VNS other methods of surgical treatment
13:00-13:10	Debate host: <i>Konrad Rejdak</i> , Poland
13:10-13:25	PRO: Oleksander Dukhovsky, Ukraine
13:25-13:40	CON: Kostyantyn Kostyuk, Ukraine
13:40-14:00	Discussion and rebuttals

HALL ELITE 2	and FLOOR
14:00-15:00	Lunch Break
Hall E	
	CHAIRS: Valeriy Kalashnikov, Ukraine; Natalia Kufterina, Ukraine
15:00-16:00	Debate: Are new generation AEDs superior to the classical antiepileptic drugs in the management of epilepsy?
	Capsule: Over the past 30 years, the number of AED has increased more than 3-fold. Many of them have been clinically tested as first-line therapy. However, the proportion of pharmacoresistant patients remains the same. Is it appropriate to designate «new» AED?
15:00-15:10	Debate host: <i>Lidiya Maryenko</i> , Ukraine
15:10-15:25	YES: Ilan Blatt, Israel
15:25-15:40	NO: Yurii Horansky, Ukraine
15:40-16:00	Discussion and rebuttals
16:00-17:00	Debate: Should we always initiate treatment after first ever epileptic seizure?
	Capsule: According to the new definition of epilepsy, the diagnosis of epilepsy is always needed after 2 unprovoked seizures. In what cases is it possible to diagnose epilepsy and start treatment after a first seizure?
16:00-16:10	Debate host: Tetyana Litovchenko, Ukraine
16:10-16:25	PRO: Konrad Rejdak, Poland
16:25-16:40	CON: Volodymyr Kharytonov, Ukraine
16:40-17:00	Discussion and rebuttals
HALL ELITE 2	nd FLOOR

24 • 25

17:00-17:15 Coffee Break

November 23-24, 2017 Kyiv, Ukraine

Friday, November 24, 2017

Hall B+C+D		
Tiali DTOTD	CHAIRS:	
	Tetyana Litovchenko, Ukraine; Volodymyr Korostiy, Ukraine	
09:00-10:00	Debate: The controversies of post-stroke epilepsy: diagnosis and clinical guidance	
	Capsule: Should we consider the first attack of post-stroke seizures as a debut of epilepsy? When should we start administration of antiepileptic drugs and what medication should be chosen?	
09:00-09:10	Debate host: <i>Konrad Rejdak</i> , Poland	
09:10-09:25	PRO: Yuriy Vorokhta, Ukraine	+
09:25-09:40	CON: Denys Khramtsov, Ukraine	
09:40-10:00	Discussion and rebuttals	
10:00-11:00	Debate: Tactics of delivery in women with epilepsy: do all women with epilepsy need operative delivery?	
	Capsule: Epileptic seizures increase the risk of infant and maternal mortality. Many clinicians consider surgical delivery necessary. How expedient surgical delivery for all women with epilepsy?	
10:00-10:10	Debate host: Yurii Horansky, Ukraine	
10:10-10:25	PRO: Andriy Dubenko, Ukraine	
10:25-10:40	CON: Lidya Maryenko, Ukraine	
10:40-11:00	Discussion and rebuttals	
HALL ELITE 2	2nd FLOOR	
11:00-11:30	Coffee Break	

TIBOMAKC



эапобігає утворенню атеросклеротичних бляшок¹



при виготовлені коллапсуючого поліпропіленового флакону застосовується сучасна технологія BSF1,2 КС - ішемічна хвороба серця, ХСН - хронічна серцева недостатність, АГ - артеріальна гіпертензія

 Δ арница

ГІВОМАКС-ДАРНИЦЯ (TIVOMAX-DARNITSA). Розчин для інфузій, 1 мл розчину містить аргініну гідрохлориду – 42 м

ІНФОРМАЦІЯ ВИКЛЮЧНО ДЛЯ РОЗМІЩЕННЯ У СПЕЦІАЛІЗОВАНИХ ВИДАННЯХ, ПРИЗНАЧЕНИХ ДЛЯ МЕДИЧНИХ УСТАНОВ ТА ЛІКАРІВ, А ТАКОЖ ВИКЛЮЧНО ДЛЯ РОЗПОВСЮДЖЕННЯ НА СЕМІНАРАХ, КОНФЕРЕНЦІЯХ, СИМПОЗІУМАХ З МЕДИЧНОЇ ТЕМАТИКИ.

3 повною інформацією про препарат можна санайомитись в інструкції для медичного застосування лікарського засобу Тівомакс-Дарница, Я П. МОЗ Україні № ЦА/1382/70/10.1 Наказ МОЗ Україні № 166 від 03.09-20/4. 1. Березні н. В. Г. Роль задотагивальной дисфункців в развитик каромаєвскувітемь забопеванній періспективы відмогическої короркции донаторами оксида азота — Уку. Мед. Часопис. 2015. П серятня (електронна публікація), умужилідотица, 2. Чурсина Т.Я. и др. Самая могущественная аминожислога кардиологиях реалии и перспективы использовання L-аргинина для регуляции микроциркуляторного кровотока. Т Пятеларі, № 15 (109) 2016.

UA.TIW.16.08.0

ПрАТ «Фармацевтична фірма «Дарниця», Україна, 02093, м. Київ, вул. Бориспільська, 13. www.darnitsa.ua



November 23-24, 2017 Kyiv, Ukraine

Thursday, November 23, 2017

П		ш	Λ
	ы	ш	W 4 1
			7 A 1

CHAIRS:

Tetyana Slobodin, Ukraine; Olena Krypchak, Ukraine

15:00-16:00 Debate:

PD with dementia and dementia with Lewy bodies – one or two separate disorders?

Capsule: DLB and PDD are important and common dementia syndromes that overlap in their clinical features, neuropathology, and management. They are believed to exist on a spectrum of Lewy body disease. The distinction between these syndromes continues to be an active clinical and research question.

15:00–15:10 Debate host: *Jaime Kulisevsky*, Spain

15:10–15:25 PRO: Yanosh Sanotsky, Ukraine

15:25–15:40 CON: *Nataliya Pavlyshyna*, Ukraine

15:40-16:00 Discussion and rebuttals

CHAIRS:

Alla Cherkez, Ukraine; Olga Bordyzhenko, Ukraine

16:00-17:00 Debate:

Depression in PD is pathogenetically associated with the risk of developing impulsive-compulsive disorders

Capsule: ICD's are especially seen in PD patients with young age of onset, higher doses of antiparkinsonian drugs, pre-existent or current depression, pre-existing recreational drug or alcohol use, and high novelty seeking personality traits. Is it worth to provide a detailed behavioral assessment, especially testing for depression before starting dopaminergic therapy, taking into account a relationship between impulsivity and depression?

16:00–16:10 Debate host: *Horst Przuntek*, Germany

16:10–16:25 PRO: *Tetyana Slobodin*, Ukraine

16:25–16:40 CON: Jaime Kulisevsky, Spain

16:40–17:00 Discussion and rebuttals

HALL ELITE 2nd FLOOR

17:00-17:15 Coffee Break

Hall A

CHAIRS:

Olga Dubenko, Ukraine; Yulia Neryanova, Ukraine

17:15-18:15 Debate:

Is the development of clinically significant autonomic disorders an undeniable sign of multisystem atrophy?

Capsule: In up to 50% of patients with MSA severe autonomic abnormalities, most frequently OH and erectile dysfunction, precede the development of the movement disorder. Resent studies suggest that peripheral postganglionic sympathetic denervation may occur earlier in PD, thus constituting the earliest stage of the disease, at least in certain patients. Is the autonomic dysfunction a reliable clinical marker of MSA, taking into account that MSA shares OH with PD and other neurodegenerative diseases with dementia?

17:15–17:25 Debate host: *Oleksander Kalbus*, Ukraine

17:25–17:40 YES: *Kateryna Karpynska*, Ukraine

17:40–17:55 NO: Gennadiy Moskovko, Ukraine

17:55–18:15 Discussion and rebuttals

in Neurology

THE 1st REGIONAL UKRAINIAN CONGRESS

November 23-24, 2017 Kyiv, Ukraine

CHAIRS:

Gennadiy Moskovko, Ukraine

18:15-19:15 Debate:

Do we have 2017 a paradigma change in the treatment of PD considering the microbiom pathology?

Capsule: The GIT could represent a vulnerable area through which pathogens could induce CNS neuro-inflammation via microglia activation. Recent concepts may suggest the modulation of the gut microbiota is an achievable strategy for innovative therapies in neurodegenerative disorders, PD in particular

18:15–18:25 Debate host: <i>Tetvana Slobot</i>	din.	Ukraine
---	------	---------

18:25–18:40 YES: *Horst Przuntek*, Germany

18:40–18:55 NO: *Dmytro Maltsev*, Ukrain*e*

18:55-19:15 Discussion and rebuttals

Friday, November 24, 2017

Hall B+C+D

CHAIRS:

Andriy Popov, Ukraine; Maryanna Slychko, Ukraine

11:30-12:30 Debate:

Are neuropsychiatric complications after DBS in patients with Parkinson's disease predictable?

Capsule: Nowadays, the main surgical treatment for Parkinson disease, dystonia, tics is deep brain stimulation (DBS), which has been reported to have consequences such as decline in verbal fluency, episodes of depression, elevated incidences of suicide, hypomania, severe and lasting behavior disturbances, which were credibly not present in the preoperative phase. Could we suspect these these side effects before the operation?

11:30–11:40 Debate host: *Irina Karaban*, Ukraine

11:40–11:55 PRO: Kostyantyn Kostyuk, Ukraine

11:55–12:10 CON: Iryna Bogdanova, Ukraine

12:10–12:30 Discussion and rebuttals

CHAIRS:

Alla Cherkez, Ukraine; Olena Krypchak, Ukraine

12:30–13:30 Debate: Whether vascular PD is a separate disease?

Capsule: Currently, Parkinson's disease (PD) and vascular parkinsonism (VP) can be considered as a different disease or is a consequence of cerebrovascular pathology?

Can cerebrovascular diseases be considered the basis for the development of Parkinson's disease? Cerebrovascular disease can be combined with Parkinson's disease, what is the tactic of pathogenetic therapy in this cases?

12:30–12:40 Debate host: Gennadiy Moskovko, Ukraine

12:40–12:55 YES: *Iryna Karaban*, Ukraine **12:55–13:10 NO**: *Iryna Bogdanova*, Ukraine

13:10-13:30 Discussion and rebuttals

HALL ELITE 2nd FLOOR

13:30-14:30 Lunch Break





OCREVUS®1,2

окрелізумаб



У рандомізованому подвійному сліпому, плацебо-контрольованому клінічному дослідженні, в якому медіана часу отримання терапії становила 3 роки (n=732)3





ІСТОТНЕ ЗНИЖЕННЯ

ризику підтвердеженого прогресування інвалідності, що зберігалася 12 тижнів, 24 тижні*³



ЗНАЧНЕ ЗМЕНШЕННЯ

ОБСЯГУ УРАЖЕННЯ на Т2-зваженому зображенні та ВТРАТИ об'єму головного мозку³



склерозу (ППРС)?

ІСТОТНО ЗНИЖУЄ ПОГІРШЕННЯ швидкості ходьби



СПРИЯТЛИВИЙ ПРОФІЛЬ БЕЗПЕКИ³



ЗАСТОСУВАННЯ кожні 6 місяців".

без рутинних обстежень на вірус ЈС, функцій серцево-судинної системи або рівня лімфоцитів 1,3

Коротка інформація щодо медичного застосування препарату ОКРЕВУС®

Коротка інформація щодо медичного застосування препарату ОКРЕВУС®
Склад: 1 флакон (10 мл концентрату для розчину для інфузій) містить 300 мг (30 мг/мл) окрелізумабуформа випуску. Концентрат для розчину для інфузій. Фармакотерапевтична грула. Селективні імуносурвесатих. Код АТХ СОФА АЗС. Фармакологічні властивості. Окрелізумаб ученть при розсінному склерозі, невідомий, однак перабажається, що межаніза дії поляга у зак'язрання з СООЗ, рецептором, присутнім на поверхні пре-В-1 зарімих. Разімфосціня. Післе закузання з СООЗ, рецептором, присутнім на поверхні пре-В-1 зарімих. Разімфосціна. Післе закузання з СООЗ, рецептором, присутнім на поверхні пре-В-1 зарімих. Разімфосціна. Післе закузання з СООЗ, рецептором, присутнім на поверхні пре-В-1 зарімих. Разімфосціна. До закузання з СООЗ, рецептором, присутнім на поверхні пре-В-1 зарімих. Разімфосціна закузання з СООЗ, рецептором, присутнім на поверхні пре-В-1 зарімих. Разімфосціна закузання з СООЗ, рецептором, присутнім на поверхні пре-В-1 зарімих. Разімфосціна закузання з СООЗ, рецептором, присутнім на поверхні пре-В-1 зарімих. Разімфосціна закузання з СООЗ, рецептором закузання з СООЗ, рецептором закузання закузання з СООЗ, рецептором закузання закузанн

Інформація наведена у скороченому вигляді. Більш детальна інформація про препарат Окревус[®] міститься в інструкції для медичного застосування лікарського засобу (затверджена Наказом МОЗ України № 1049 від 04.09.2017.) Ресстраційне посвідчення МОЗ України № UA/16278/01/01 від 04.09.2017.) Перед застосуванням уважно ознайомтеся з інструкцією для медичного застосування лікарського засобу Окревус[®]. Інформація для професійної діяльності медичних і фармацевтичних працівників.

in primary progressive multiple sclerosis, N Engl J Med, 2017;376(3):209-220,



MULTIPLE SCLEROSIS

November 23-24, 2017 Kyiv, Ukraine

Thursday, November 23, 2017

CHAIRS:

Tetyana Muratova, Ukraine

15:00-16:00 Debate:

There is a link between a deficiency in the body of vitamin D and the onset of MS. Do we need to include, vitamin D as an adjunctive therapy?

Capsule: Vitamin D insufficiency considered to be a modifiable risk factor for MS onset. About 1 billion people around the world have vitamin D deficiency or insufficiency. Can we recommend to patients with multiple sclerosis to use nutritional supplements with vitamin D for treatment?

15:00–15:10 Debate host: *Olga Shulga*, Ukraine

15:10–15:25 YES: *Larysa Sokolova*, Ukraine

15:25–15:40 NO: Valeryi Pashkovsky, Ukraine

15:40–16:00 Discussion and rebuttals

16:00-17:00 **Debate**:

What are the priorities today in the treatment of MS - Anti-B-cell or nonspecific anti-B + T-therapy?

Capsule: Earlier concepts focused mainly on T-lymphocytes as the key cell type to mediate inflammatory damage within CNS lesions, emerging evidence suggests that B lymphocytes may play an important role both as the precursors of antibody secreting cells and as antigen presenting cells for the activation of T-cells. What should be our target? Specific anti-B-cells therapy or non-specific anti-B+T-therapy is our priority?

16:00–16:10 Debate host: *Natalia Voloshina*, Ukraine

16:10–16:25 PRO: *Tetyana Nehrych*, Ukraine

16:25–16:40 CON: *Olga Shulga*, Ukraine

16:40–17:00 Discussion and rebuttals

HALL ELITE 2nd FLOOR

17:00-17:15 Coffee Break

CHAIRS:

Valeryi Pashkovsky, Ukraine

17:15-18:15 Debate:

Primary-progredient MS is a type of flow or an individual disease?

Capsule: 15% of MS patients have a progressive form at disease with gradual worsening of neurological status for at least 1 year. Diagnosis of primary progredient MS is a challenge and some authors consider that it is an individual nosology or even the same disease with secondary progressive MS. Should we revise classification of MS?

ciassification of wo:

17:15–17:25 Debate host: *Olena Myalovytska*, Ukraine

17:25–17:40 PRO: *Larysa Sokolova*, Ukraine

17:40–17:55 CON: Olena Tsurkalenko, Ukraine

17:55–18:15 Discussion and rebuttals

November 23-24, 2017 Kyiv, Ukraine

Friday, November 24, 2017

Hall F

CHAIRS:

Tetyana Nehrych, Ukraine

09:00-10:00 Debate:

Acute demyelinating encephalomyelitis (ADEM) – if this is clinical form of multiple sclerosis or various disease? Whether it is necessary to appoint or nominate modifying therapy at ADEM?

Capsule: Acute disseminated ebcephalomyelitis (ADEM) is an immune-mediated inflammatory demyelinating condition that predominately affects white matter of the brain and spinal cord. The division between MS and ADEM is indistinct suggesting clinical continuum. Could we consider that ADEM is just a form of MS? Could we prescrive any modyfying therapy at ADEM?

09:00-09:10 Debate host: *Tetyana Nehrych*, Ukraine

09:10-09:25 PRO: Tetyana Muratova, Ukraine

09:25-09:40 CON: Tetiana Kobys, Ukraine

09:40-10:00 Discussion and rebuttals

10:00-11:00 Debate:

Should the modifying therapy be discontinued at the signs of secondary progression and when?

Capsule: About 70% of patients with relapsing-remitting multiple sclerosis (RRMS) develop secondary progressive multiple sclerosis (SPMS) for 15–20 years of the disease, and in 25 years – 90%. The exact role of modifying the disease in delaying this transition remains unclear. Does the main dilemma facing doctors make sense to continue to treat drugs that are effective in relapsing-remitting multiple sclerosis, as the disease progresses to the secondary progressive MS. In the treatment of SPMS, this treatment seems to be losing its benefits, and since it often involves serious side effects and high costs, the clinicians have to decide whether to stop the treatment and when to do it?

10:00–10:10 Debate host: *Larysa Sokolova*, Ukraine

10:10-10:25 PRO: Olena Tsurkalenko, Ukraine

10:25-10:40 CON: Horst Przuntek, Germany

10:40–11:00 Discussion and rebuttals

HALL ELITE 2nd FLOOR

11:00-11:30 Coffee Break

Hall F

CHAIRS:

Tetyana Muratova, Ukraine

11:30-12:30 Debate:

Can we prescribe/continue modifying therapy during pregnancy? What drugs should we prefer?

Capsule: MS is more prevalent in women of reproductive age than in any other population group. There is no evidence that MS impairs fertility or leads to an increased number of spontaneous abortions, stillbirths or congenital malformations. Several studies of large numbers of women have repeatedly demonstrated that pregnancy, labor, delivery and the incidence of fetal complications are no different in women who have MS than in control groups without the disease. However there are no evidence of the necessity of MT during pregnancy as well as about the choice of MSMT.

11:30–11:40 Debate host: *Tetyana Muratova*, Ukraine

11:40–11:55 PRO: *Natalia Voloshina*, Ukraine


11:55–12:10 CON: Tetyana Nehrych, Ukraine

12:10–12:30 Discussion and rebuttals

38 - 39



1 in 3 Patients will not Respond Adequately to Anti-Epileptic Drugs





VNS Therapy® - is an implantable medical device for Drug-Resistant Epilepsy (DRE)

VNS Therapy is an easy to use treatment that controls seizures by sending mild pulses from the generator to the left vagus nerve at regular intervals all day, every day.

Can be safely be used as an adjunctive treatment, offering proven therapeutic outcomes.

VNS = Vagus Nerve Stimulation

To discover how VNS Therapy could help your DRE Patients visit www.vnstherapy.com

AspireSR® is CF mark approved and commercial distribution may vary by country

VNS THERAPY EUROPEAN INDICATION FOR USE

VNS Therapy is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to seizure medications. The Model 106 AspireSR* (Seizure Response) features the Automatic Stimulation Mode, which is intended for patients who experience seizures that are associated with oradiac infythm increases known as icotal tachycardia.

CONTRAINDICATIONS: The VNS Therapy system cannot be used in patients after a bilateral or left cervical vagatomy. Do not use short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy on patients implanted with the VNS Therapy system. Diagnostic ultrasound is not included in this contraindication. Cardiac arrhythmia (Model 160 only)—The AutoStim Mode feature should not be used in patients with clinically meaningful arrhythmias or who are using treatments that interfere

WARNINGS: Physicians should inform patients about all potential risks and adverse events discussed in the WNS Therapy Physician Manuais, including information that VNS Therapy may not be a cure for epilepsy. Since setures may occur unexpectedly, patients should consult with a physician before engaging in unsupervised activities, such as driving, swimming, and bathing, or in strenuous sports that could harm them or others. A malfunction of the VNS Therapy system could cause painful or direct current stimulation, which could result in nerve damage. Removal or replacement of the VNS Therapy system requires an additional surgical procedure. Patients who have pre-existing swallowing.

cardiac, or respiratory difficulties (including, but not limited to, obstructive sleep apnea and chronic pulmonary disease) should discuss with their physicians whether VNS Threapy is appropriate for them since there is the possibility that stimulation might worsen their condition. Postoperative bradycardia can occur among patients with certain underlying cardiac arrhythmias. MRI can be safely performed; however, special equipment and procedures must be used.

ADVERSE EVENTS: The most commonly reported side effects from stimulation include hoarseness (voice alteration), paresthesia (prickling feeling in the skin), dyspnea (shortness of breath), sore throat and increased coughing. The most commonly reported side effect from the implant procedure is infection.

*The information contained here represents partial excerpts of important prescribing information from the product labeling. Patients should discuss the risks and benefits of VNS Therapy with their healthcare provider. Visit www.VNSTherapy.com for more information.

OUSADBS15-11-1000-EEA
CYBERONICS EUROPE BVBA

WHOLLY-OWNED SUBSIDIARY OF LIVANOVA PLC Airport Plaza Kyoto Building Leonardo Da Vincilian 19 B-1831 Diegem, Belgium Tel: +32.2.720,95,95 Fax: +32.2.720,60,55 100 Cyberonics Boulevard Houston, Texas 77058 Tel: +1.800.332.1375 Fax: +1.281.218.9332



NEUROPSYCHIATRY AND BEHAVIORAL NEUROLOGY



November 23-24, 2017 Kyiv, Ukraine

Thursday, November 23, 2017

		Hall B+C+D	
Hall B+C+D	CHAIRS: Horst Przuntek, Germany;		CHAIRS: Morris Freedman, Canada; Mikhaylo Oros, Ukraine
	Tetyana Slobodin, Ukraine	15:00-16:00	Debate: Is it relevant to use VNS therapy in depression?
12:00-13:00	Debate: Does Bilingualism Delay the Onset of Alzheimer's Disease		Capsule: Vagus nerve stimulation (VNS) was approved by the FDA for the treatment of severe, recurrent unipolar and bipolar depression
	Capsule: There is evidence that speaking more than one language delays the onset of dementia but this is not universally accepted		in July of 2005. But, VNS is not a rapid treatment for depression: studies show that, on average, it may take up to 9 months for
12:00-12:10	Debate host: Nina Sofilkanych, Ukraine		a treatment response to occur
12:10-12:25	PRO: Morris Freedman, Canada	15:00-15:10	Debate host: <i>Kostyantyn Kostyuk</i> , Ukraine
12:25-12:40	CON: Andriy Dubenko, Ukraine	15:10-15:25	PRO: Volodymyr Korostiy, Ukraine
12:40-13:00	Discussion and rebuttals	15:25-15:40	CON: Olga Mostova, Ukraine
		15:40-16:00	Discussion and rebuttals
13:00-14:00	Debate: Is mild cognitive impairment (MCI) a useful concept?	16:00-17:00	Debate: Is beta-amyloid still a relevant target in AD therapy?
	Capsule: Within the framework of AD, preclinical cognitive impairment is usually captured using the term MCI. Do we need this term?		Capsule: Accumulation of type 2 beta-amyloid is a proven link in the pathogenesis of AD, but today there have been other hypotheses that may be more promising in terms of treating AD
13:00-13:10	Debate host: <i>Olga Mostova</i> , Ukraine	16:00-16:10	Debate host: Volodymyr Korostiy, Ukraine
13:10-13:25	PRO: Volodymyr Korostiy, Ukraine	16:10-16:25	YES: Nina Sofilkanych, Ukraine
13:25-13:40	CON: Morris Freedman, Canada	16:25-16:40	NO: Amos D. Korczyn, Israel
13:40-14:00	Discussion and rebuttals	16:40-17:00	Discussion and rebuttals
HALL ELITE 2	and FLOOR	HALL ELITE 2	2nd FLOOR
14:00-15:00	Lunch Break	17:00-17:15	Coffee Break

NEUROPSYCHIATRY AND BEHAVIORAL NEUROLOGY



THE 1st REGIONAL UKRAINIAN CONGRESS

November 23-24, 2017 Kyiv, Ukraine

Hall B+C+D	
	CHAIRS: Morris Freedman, Canada; Volodymyr Kharytonov, Ukraine
17:15-18:15	Debate: Is AD a non-specific manifestation of aging?
	Capsule: AD is a disease that can occur in any person if you live long enough
17:15-17:25	Debate host: <i>Andriy Dubenko</i> , Ukraine
17:25-17:40	PRO: Amos D. Korczyn, Israel
17:40-17:55	CON: Volodymyr Korostiy, Ukraine
17:55-18:15	Discussion and rebuttals
18:15-19:15	Debate: Does depression contribute to dementia?
	Capsule: «Cold» violations of cognitive functions in depression & affective disorders of cognitive functions in dementia - pathogenetic affinity or comorbidity?
18:15-18:25	Debate host: Nina Sofilkanych, Ukraine
18:25-18:40	PRO: Olga Mostova, Ukraine
18:40-18:55	CON: Volodymyr Korostiy, Ukraine
18:55-19:15	Discussion and rebuttals

Неогабін

Прегабалін



Позбався від болю, ПОРИНЬ У ЖИТТЯ

■ Доведена ефективність при нейропатичному болю, фіброміалгії та генералізованому тривожному розладі^{1–6}

 Доведена біоеквівалентність оригінальному прегабаліну⁷

 Один з найдоступніших за ціною прегабалінів в Україні⁸



Скорочена інструкція для медичного застосування препарату НЕОГАБІН 75, 150
Діюча речовина. Прегабалін зійзується з допоміжною субодиницею (альфа?-дельта-білок) потенціалозалежних кальцієвих кальпіцевих кналів у центральній нервовій системі. Показання, невропатичний біль. Еліпепсія, Генеративість, радіомої речовини або будь-якої із допоміжних речовин. Побічні реакції. Запаморочення і сонливість, посилення аленту, сплутаність свідомості, дезорівстація, дратівливість, еффоричний настрій, зниження лібі-дю, безсоння, атаксія, порушення кординації, порушення вірновати, розлади увати, погіршення дазатрія, парестезія, седація, в'ялість, головонний біль. детаргів, чечіткість зору, диплопія, ком'юнктивіт, вертиго, біловання, запор, сухість у роті, метеоризм, тастроентерит, еректильна дисфункція, імпотенція, периферичний набряк, нобряки, порушення ходи, відмуття стіяніння, втома, збільшення маси тіла тощо. Категорія відпуску, за рецептом. Р. П. МОЗ України. № UA/13702/01/01, № UA/13702/01/02, Наказ МОЗ України від 04.02.2016 №65. Виробник: ТОВ «Фарма Старт», україна, оз 33124, м. Київ, бульвар І. Яелес, 8. ТОВ «Фарма Старт» входить до гути компаній Асіно (Швейцарія). Повна інформації янаждиться в інструкцях для медичного застосування препартів. Неформацій для медичних і фармацетниких рамагивитьмих на лікарів, ціля розловослуження в семінарах, комференційх, симпозіумах з медичног гомагики.

1. Arezz J.C. et al. BMC Neurology 2008: 8:33. 2. Dworkin R.H. et al. Neurology 2003; 60; 1274–83. 3. Croffrd L.J. et al. Pain 2008; 136(3):419–31. 4. Amold L.M. et al. J Pain. 2008 Sep; 99):792–805. 5. Rickels K. et al. Arch Gen Psychiatry. 2005 Sep; 62(9):1022–30. 6. Baldwin D.S. et al. Neuropsychiatr Dis Treat. 2013; 9:883–27. Клінічне дослідження з оцінки біосемівівалентності лікарських препаратів. Код дослідження ТРМЕР-5. Заключний звіт, 2014, стор. 8. в. Тижневим «Аптека», www.apteka.u.g.



ТОВ Фарма Старт | бульвар Івана Лепсе, 8 | Київ | 03124 | Україна Компанія Асіпо Group, Швейцарія | www.acino.ua

HEADACHE & PAIN

November 23-24, 2017 Kyiv, Ukraine

Friday, November 24, 2017

CHAIRS:

Mikhaylo Oros, Ukraine; Messoud Ashina, Denmark

09:00-10:00 Debate: Can response to triptan be used to diagnose migraine?

Capsule: No specific diagnostic test is available to diagnose primary headaches. Triptans are selective serotonin receptor agonists developed to treat migraine. Can triptans be used to treat other pirmary headaches? Can we use triptan response to diagnose migraine?

09:00–09:10 Debate host: *Igor Romanenko*, Ukraine

09:10-09:25 PRO: *George Gegelashvili*, Georgia

09:25-09:40 CON: Messoud Ashina, Denmark

09:40–10:00 Discussion and rebuttals

10:00-11:00 Debate:

Microvascular decompression should be considered as first line approach in trigeminal neuralgia

Capsule: Trigeminal neuralgia treatment usually starts with preventive medications. Pharmacological treatment is often associated with intolerable and numerous adverse effects. Microvascular decompression (MVD), also known as the Jannetta procedure, is a neurosurgical procedure to treat trigeminal neuralgia. Should MVD be considered as first line approach in managment of trigeminal neuralgia?

10:00–10:10 Debate host: *Volodymyr Smolanka*, Ukraine

10:10-10:25 PRO: George Gegelashvili, Georgia

10:25–10:40 CON: Aydin Gozalov, Denmark

10:40-11:00 Discussion and rebuttals

Hall ELITE 2nd floor

11:00-11:30 Coffee Break

Hall A

CHAIRS:

Mikhaylo Oros, Ukraine; Messoud Ashina, Denmark

11:30-12:30 Debate:

Antidepressant medications are effective in migraine

Capsule: Epidemiological have shown that migraine is comorbid with depression. Antidepressants are often prescribed for migraines. Can antidepressants prevent and treat headaches?

11:30-11:40 Debate host: *Igor Romanenko*, Ukraine

11:40–11:55 YES: Dimos Mitsikostas, Greece

11:55–12:10 NO: *Lars Bendtsen*. Denmark

12:10–12:30 Discussion and rebuttals

12:30-13:30 Debate:

Multiple-drug combinations are effective in migraine and cluster

headache

Capsule: Should we use combined treatment in clinical practice? Some headache experts recommend to combine multiple drug combinations for migraine and cluster headache. Is there sufficient evidence to support combined treatment?

12:30–12:40 Debate host: Valeriy Kalashnikov, Ukraine

12:40-12:55 PRO: Lars Bendtsen, Denmark

12:55-13:10 CON: Mikhaylo Oros, Ukraine

13:10-13:30 Discussion and rebuttals

Hall ELITE 2nd floor

13:30-14:30 Lunch Break

November 23-24, 2017 Kyiv, Ukraine

Hall A	
	CHAIRS: George Gegelashvili, Georgia; Volodymyr Romanenko, Ukraine
14:30-15:30	Debate: Migraine and tension-type headache is the same disorder
	Capsule: Tension-type headache is the most common headache type in the world. Some patients describe a daily tension-type headache as well as a recurrent migraine attacks. Should these patients be diagnosed as coexisting migraine and tension-type headache? Or is migraine and tension-type headache the same disorder?
14:30-14:40	Debate host: Natalia Kufterina, Ukraine
14:40-14:55	PRO: Volodymyr Romanenko, Ukraine
14:55-15:10	CON: Messoud Ashina, Denmark
15:10-15:30	Discussion and rebuttals
15:30-16:30	Debate: Persistent idiopathic facial pain is a manifestation of somatoform disorder
	Capsule: The issue of manifestation of somatoform pain syndrome has existed for more than 150 years, but has not been resolved to this day. Is there an organic substrate of idiopathic pain in the face or not?
15:30-15:40	Debate host: <i>Volodymyr Korostiy</i> , Ukraine
15:40-15:55	YES: Dimos Mitsikostas, Greece
15:55-16:10	NO: Aydin Gozalov, Denmark
16:10-16:30	Discussion and rebuttals
16:30	CLOSING CEREMONY

INDUSTRY SUPPORTED SYMPOSIUM





SUPPORTED BY ROCHE

THE 1st REGIONAL UKRAINIAN CONGRESS

November 23-24, 2017 Kyiv, Ukraine

Thursday, November 23, 201

		ı	
п			
	rai		

CHAIRS:

Tetyana Nehrych, Ukraine

12:00–13:30 Multiple sclerosis: change in treatment paradigm

Industry supported symposium

Non-CME session, Supported by Roche

12:00-12:10 Introduction

12:10–12:30 A new concept in the pathogenesis of multiple sclerosis –

key role of B cells

Tetyana Nehrych, Ukraine

12:30–12:50 *Progress in diagnostics and monitoring of multiple sclerosis*

course

Larysa Sokolova, Ukraine

12:50–13:10 Ocrelizumab – from clinical trials to the practical using

Natalia Voloshina, Ukraine

13:10-13:30 Questions & Answers. Discussion

HALL ELITE 2nd FLOOR

14:00-15:00 Lunch Break



SUPPORTED BY SANOFI GENZYME

THE 1st REGIONAL UKRAINIAN CONGRESS

November 23-24, 2017 Kyiv, Ukraine



Friday, November 24, 2017

BREAKFAST WITH EXPERT

Hall VENICE 2nd floor

08:00-09:00 Breakfast with expert

Meet the expert session
TREATABLE NEUROMUSCULAR
DISEASES.
POMPE DISEASE.

Non-CME session,

Supported by Sanofi Genzyme

Prof. Andoni Urtizberea, France









CHAIRPERSONS

Amos D. Korczyn, Israel

Jaroslaw Slawek, Poland

MAIN TOPICS

www.comtecmed.com/cony | cony@comtecint.com

- · Alzheimer's disease and dementia
- Epilepsy
- Headache
- · History of neurology in Poland
- Multiple sclerosis
- Neuroimmunology

- · Parkinson's disease
- · Other movement disorders
- Rehabilitation
- Sleep
- Stroke
- · Wilson's disease



Friday, November 24, 2017



YOUNG INVESTIGATION SCHOLARSHIP

Hall E	
	CHAIRS:
	Natalia Kufterina, Ukraine Andriy Dubenko , Ukraine
11:30-12:30	YOUNG INVESTIGATOR SCHOLARSHIP oral and visual presentations
11:30-11:35	Introduction
11:35-11:40	Frequency of status epilepticus in women with epilepsy
	Abramov, H. Odintsova, Ulytyn, Saint Petersburg, Russia
11:40-11:45	Characteristics of Multiple sclerosis relapses and factors affecting relapses frequency in patients with immunolodulatory therapy
	Myroslav Bozhenko, Olga Shulga, Lutsk, Ukraine
11:45-11:50	Importance of EEG-video monitoring for differential diagnosis of epileptic and non-epileptic peroxysmal states
	Anna Voitiuk, Kharkiv, Ukraine
11:50-11:55	Cardiovascular effects of antiepileptic drugs
	Valeriya Grymaylo, Kharkiv, Ukraine
11:55-12:00	Detection of neuro-psychiatric disorders among medical students
	Anastasiya Makarova, Maryna Ziuzina, Kharkiv, Ukraine
12:00-12:05	Correlations of clinical and neuroimaging features in small vessel disease due to arterial hypertension and cerebral atherosclerosis
	Mykola Petrenko, Kyiv, Ukraine
12:05-12:10	Impact of educational stress on the development of migraine in students
12.00 12.10	Vita Shchebetenko, Kharkiv, Ukraine
12:10-12:30	Discussion and summarizing

PARTNERSHIP AND SUPPORT























SUPPORTERS





ТОВ РАНБАКСІ ФАРМАСЬЮТІКАЛС VKPAÏHA





MEDIA SUPPORT







